Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye

Topical drug delivery is one of the most challenging aspects of eye therapy. Eye drops are the most prevalent drug form, especially for widely distributed anterior segment eye diseases (cataracts, glaucoma, dry eye syndrome, inflammatory diseases, etc.), because they are convenient and easy to apply...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander Vaneev, Victoria Tikhomirova, Natalia Chesnokova, Ekaterina Popova, Olga Beznos, Olga Kost, Natalia Klyachko
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ocular drug delivery anterior segment of the eye nanoparticles nanomicelles in situ gels ocular barriers Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/82f2a6dc68244664b96aca5310ae49a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:82f2a6dc68244664b96aca5310ae49a6
record_format	dspace
spelling	oai:doaj.org-article:82f2a6dc68244664b96aca5310ae49a62021-11-25T17:55:45ZNanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye10.3390/ijms2222123681422-00671661-6596https://doaj.org/article/82f2a6dc68244664b96aca5310ae49a62021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12368https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Topical drug delivery is one of the most challenging aspects of eye therapy. Eye drops are the most prevalent drug form, especially for widely distributed anterior segment eye diseases (cataracts, glaucoma, dry eye syndrome, inflammatory diseases, etc.), because they are convenient and easy to apply by patients. However, conventional drug formulations are usually characterized by short retention time in the tear film, insufficient contact with epithelium, fast elimination, and difficulties in overcoming ocular tissue barriers. Not more than 5% of the total drug dose administered in eye drops reaches the interior ocular tissues. To overcome the ocular drug delivery barriers and improve drug bioavailability, various conventional and novel drug delivery systems have been developed. Among these, nanosize carriers are the most attractive. The review is focused on the different drug carriers, such as synthetic and natural polymers, as well as inorganic carriers, with special attention to nanoparticles and nanomicelles. Studies in vitro and in vivo have demonstrated that new formulations could help to improve the bioavailability of the drugs, provide sustained drug release, enhance and prolong their therapeutic action. Promising results were obtained with drug-loaded nanoparticles included in in situ gel.Alexander VaneevVictoria TikhomirovaNatalia ChesnokovaEkaterina PopovaOlga BeznosOlga KostNatalia KlyachkoMDPI AGarticleocular drug deliveryanterior segment of the eyenanoparticlesnanomicellesin situ gelsocular barriersBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12368, p 12368 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ocular drug delivery anterior segment of the eye nanoparticles nanomicelles in situ gels ocular barriers Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	ocular drug delivery anterior segment of the eye nanoparticles nanomicelles in situ gels ocular barriers Biology (General) QH301-705.5 Chemistry QD1-999 Alexander Vaneev Victoria Tikhomirova Natalia Chesnokova Ekaterina Popova Olga Beznos Olga Kost Natalia Klyachko Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
description	Topical drug delivery is one of the most challenging aspects of eye therapy. Eye drops are the most prevalent drug form, especially for widely distributed anterior segment eye diseases (cataracts, glaucoma, dry eye syndrome, inflammatory diseases, etc.), because they are convenient and easy to apply by patients. However, conventional drug formulations are usually characterized by short retention time in the tear film, insufficient contact with epithelium, fast elimination, and difficulties in overcoming ocular tissue barriers. Not more than 5% of the total drug dose administered in eye drops reaches the interior ocular tissues. To overcome the ocular drug delivery barriers and improve drug bioavailability, various conventional and novel drug delivery systems have been developed. Among these, nanosize carriers are the most attractive. The review is focused on the different drug carriers, such as synthetic and natural polymers, as well as inorganic carriers, with special attention to nanoparticles and nanomicelles. Studies in vitro and in vivo have demonstrated that new formulations could help to improve the bioavailability of the drugs, provide sustained drug release, enhance and prolong their therapeutic action. Promising results were obtained with drug-loaded nanoparticles included in in situ gel.
format	article
author	Alexander Vaneev Victoria Tikhomirova Natalia Chesnokova Ekaterina Popova Olga Beznos Olga Kost Natalia Klyachko
author_facet	Alexander Vaneev Victoria Tikhomirova Natalia Chesnokova Ekaterina Popova Olga Beznos Olga Kost Natalia Klyachko
author_sort	Alexander Vaneev
title	Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
title_short	Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
title_full	Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
title_fullStr	Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
title_full_unstemmed	Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
title_sort	nanotechnology for topical drug delivery to the anterior segment of the eye
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/82f2a6dc68244664b96aca5310ae49a6
work_keys_str_mv	AT alexandervaneev nanotechnologyfortopicaldrugdeliverytotheanteriorsegmentoftheeye AT victoriatikhomirova nanotechnologyfortopicaldrugdeliverytotheanteriorsegmentoftheeye AT nataliachesnokova nanotechnologyfortopicaldrugdeliverytotheanteriorsegmentoftheeye AT ekaterinapopova nanotechnologyfortopicaldrugdeliverytotheanteriorsegmentoftheeye AT olgabeznos nanotechnologyfortopicaldrugdeliverytotheanteriorsegmentoftheeye AT olgakost nanotechnologyfortopicaldrugdeliverytotheanteriorsegmentoftheeye AT nataliaklyachko nanotechnologyfortopicaldrugdeliverytotheanteriorsegmentoftheeye
_version_	1718411813626839040

Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye

Ejemplares similares